NCT06761846View on ClinicalTrials.gov

Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions
Gastric AdenocarcinomaEsophagogastric Junction Adenocarcinoma
Interventions
BIOLOGICAL

Sintilimab plus Chemotherapy

chemotherapy includes SOX and XELOX

Trial Locations (1)

100021

RECRUITING

Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER